2019
Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis
Kaplan DE, Serper M, Mehta R, Fox R, John B, Aytaman A, Baytarian M, Hunt K, Albrecht J, Njei B, Taddei TH, Group V. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019, 156: 1693-1706.e12. PMID: 30660733, DOI: 10.1053/j.gastro.2019.01.026.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularCholesterolFemaleHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLiver CirrhosisLiver NeoplasmsMaleMiddle AgedMyocardial InfarctionPropensity ScoreProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesStrokeSurvival RateUnited StatesConceptsRetrospective cohort studyStatin exposureLarge national cohortHepatic decompensationStatin useCohort studyHazard ratioNational cohortMultivariable Cox proportional hazards modelsCox proportional hazards modelBaseline total cholesterolPrior statin exposureStatin-naïve subjectsEffect of hypercholesterolemiaVeterans Health AdministrationProportional hazards modelHepatocellular carcinoma developmentDecrease of mortalityRisk-set matchingChild-TurcottePugh classStatin therapyDL increaseTotal cholesterolHepatic functionNational Trends in Use of Opioid Drugs Among Cirrhosis-related Hospitalizations in the United States, 2004 to 2012
McCarty TR, Haque L, Njei B. National Trends in Use of Opioid Drugs Among Cirrhosis-related Hospitalizations in the United States, 2004 to 2012. Journal Of Clinical Gastroenterology 2019, 53: 78-79. PMID: 27984400, DOI: 10.1097/mcg.0000000000000771.Peer-Reviewed Original Research
2016
Use of transient elastography in patients with HIV–HCV coinfection: A systematic review and meta‐analysis
Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV–HCV coinfection: A systematic review and meta‐analysis. Journal Of Gastroenterology And Hepatology 2016, 31: 1684-1693. PMID: 26952020, PMCID: PMC5014713, DOI: 10.1111/jgh.13337.Peer-Reviewed Original ResearchMeSH KeywordsCoinfectionElasticity Imaging TechniquesHepatitis CHIV InfectionsHumansLiver CirrhosisSensitivity and SpecificityConceptsHIV-HCV coinfectionTransient elastographyMeta-regression analysisDiagnostic accuracyLiver stiffnessModerate fibrosisPooled sensitivityHCV mono-infected individualsMono-infected individualsCD4 cell countCochrane Library databasesAssessment of cirrhosisSearch of PubMedNoninvasive imaging modalityNegative likelihood ratioWeb of ScienceLiver fibrosisInclusion criteriaLibrary databasesCirrhosisCell countSystematic reviewPublication biasPatientsFibrosisOptimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD scoreBeta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters
Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut 2016, 65: 1393. PMID: 27207973, DOI: 10.1136/gutjnl-2016-312129.Peer-Reviewed Original Research